expressing tumors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9114101
APP PUB NO 20140170179A1
SERIAL NO

13714273

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Described are particular fragments of the cyclin-dependent kinase inhibitor p16 capable of increasing IFN-γ secretion of T cells or inducing proliferation of T cells and the use of said fragments for immunizing an individual against HPV-associated or other p16INK4a expressing carcinomas, preferably advanced carcinomas.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kloor, Matthias Ludwigshafen, DE 7 14
Reuschenbach, Miriam Heidelberg, DE 5 14
Von, Knebel-Doeberitz Magnus Heidelberg, DE 11 86

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 25, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00